Tag: Chemotherapy
FDA Approves First Immunotherapy Drug for Breast Cancer
Combo of Tecentriq and chemo given accelerated approval for triple-negative breast cancer
Long-Term Cardiomyopathy Risk Varies by Chemo Agent
Decreased risk seen for daunorubicin versus doxorubicin among survivors of childhood cancer
Chemo-Radiation Combo Tied to Higher Survival in Peds Hodgkin
Five-year overall survival higher in patients who receive combined tx than those treated with chemo alone
Childhood Hodgkin Lymphoma Survivors at Risk for Later Cancers
Survivors have 14-fold increased risk for developing a solid subsequent malignant neoplasm
Myelodysplastic Syndrome/AML Risk Increased After Chemo
Since 2000, risks for therapy-related myelodysplastic syndrome, AML up after chemo for solid cancers
Modified-FOLFIRINOX Beneficial in Resected Pancreatic Cancer
Disease-free, overall survival significantly longer compared with gemcitabine, but more adverse events
Cisplatin Superior to Cetuximab for HPV+ Oropharyngeal Cancer
Toxicity similar in two treatment groups at 24 months, but worse tumor control with cetuximab
Apixaban Prevents VTE in Cancer Patients Initiating Chemotherapy
Major bleeding occurred in more apixaban-treated than control patients
SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo
ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
Median progression-free survival improved with A+CHP vs CHOP; similar incidence of adverse events
